Nitric oxide (NO) and cytochrome P450 (CYP450)-mediated eicosanoids, especially 20-hydroxyeicosatetraenoic acid (20-HETE) are important determinants of a number of integrated body functions, including maintenance of vascular tone and renal function; hence, they are implicated in the genesis of hypertension. As the physiological actions of NO are attributable to the oxidation of iron, NO thereby modulates the activity of hemoproteins like the CYP450 enzyme system. The NO system is, therefore, an endogenous regulatory pathway for CYP450 eicosanoid production. NO also modulates the production/activity of other humoral factors, notably, endothelin (ET) peptides. Following inhibition of NO synthase (NOS), the ensuing renal hemodynamic changes which have been mainly attributable to withdrawal of NO may, therefore, reflect enhanced expression of vasoconstrictor CYP450 eicosanoids, especially 20-HETE and/or ET peptides. Based on: 1) reduced renal microsomal synthesis of HETEs by nitroprusside, an NO donor; 2) attenuation of the renal responses to Nw-nitro-L-arginine methyl ester (L-NAME), a NOS inhibitor, by 12,12 dibromododec enoic acid (DBDD), an inhibitor of 20-HETE synthesis, and BMS182874, an ETA receptor antagonist; and 3) ET-1-induced renal release of 20-HETE, we hypothesize that NO inhibition of endogenous 20-HETE production, possibly linked to ET production, is an important homeostatic mechanism for maintenance of vascular tone and renal function. We further propose that 20-HETE is a counterregulator of NO activity.
The Specific Aims of this proposal, therefore, are: 1) to determine the effect of NO on CYP450-dependent arachidonic acid (AA) metabolism and on the renal expression of CYP4A mRNA and protein; 2) to establish the contribution of 20-HETE to the renal hemodynamic and excretory responses induced by L-NAME; and 3) to determine if the involvement of 20-HETE in L-NAME response is linked to ET peptides. Conversion of AA to 20-HETE will be evaluated in renal microsomes incubated with NOdonors, and in microsomes from rats treated with L-arginine or L-NAME. Urinary production of 20-HETE and ET-1 will be determined in rats treated with the same agents. The mechanism of the reduced production of 20-HETE by NO will be evaluated by determining the expression of CYP4A mRNA and protein. Acute renal clearance studies will be performed to establish the contribution of 20-HETE in the renal functional response to administration of L-NAME. The role of 20-HETE in the dynamic relationship between vascular and tubular effects following NOS inhibition will also be examined in chronic studies in which hypertension will be induced with L-NAME. As ET-1, which we showed to stimulate 20-HETE production has also been shown to increase following L-NAME treatment, we will determine if 20-HETE production has also been shown to increase following L-NAME treatment, they will determine if 20-HETE production is coupled to ET production/activation of ET receptors and, if so, which receptors are involved. These studies should enhance our knowledge of the interplay between NO, 20-HETE and ET-1; endogenous regulators of renal function and systemic hemodynamics, and thus help our understanding of the pathophysiology of conditions characterized by inadequate production of NO.

National Institute of Health (NIH)
National Heart, Lung, and Blood Institute (NHLBI)
Research Project (R01)
Project #
Application #
Study Section
General Medicine B Study Section (GMB)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Texas Southern University
Internal Medicine/Medicine
Schools of Education
United States
Zip Code
Oyekan, Adebayo (2011) PPARs and their effects on the cardiovascular system. Clin Exp Hypertens 33:287-93
Fidelis, Paul; Wilson, Leticia; Thomas, Kayama et al. (2010) Renal function and vasomotor activity in mice lacking the Cyp4a14 gene. Exp Biol Med (Maywood) 235:1365-74
Yousefipour, Zivar; Oyekan, Adebayo; Newaz, Mohammad (2009) Role of G protein-coupled receptor kinase-2 in peroxisome proliferator-activated receptor gamma-mediated modulation of blood pressure and renal vascular reactivity in SHR. Am J Nephrol 30:201-8
Obih, Patience; Oyekan, Adebayo O (2008) Regulation of blood pressure, natriuresis and renal thiazide/amiloride sensitivity in PPARalpha null mice. Blood Press 17:55-63
Blanton, Ahmad; Nsaif, Rami; Hercule, Hantz et al. (2006) Nitric oxide/cytochrome P450 interactions in cyclosporin A-induced effects in the rat. J Hypertens 24:1865-72
Newaz, Mohammad; Yousefipour, Zivar; Oyekan, Adebayo (2006) Role of PPAR-gamma on the pathogenesis and vascular changes in glycerol-induced acute renal failure. Pharmacol Res 54:234-40
Newaz, Mohammad A; Yousefipour, Zivar; Oyekan, Adebayo (2006) Oxidative stress-associated vascular aging is xanthine oxidase-dependent but not NAD(P)H oxidase-dependent. J Cardiovasc Pharmacol 48:88-94
Long, David A; Newaz, Mohammad A; Prabhakar, Sharma S et al. (2005) Loss of nitric oxide and endothelial-derived hyperpolarizing factor-mediated responses in aging. Kidney Int 68:2154-63
Newaz, Mohammad; Blanton, Ahmad; Fidelis, Paul et al. (2005) NAD(P)H oxidase/nitric oxide interactions in peroxisome proliferator activated receptor (PPAR)alpha-mediated cardiovascular effects. Mutat Res 579:163-71
Oyekan, Adebayo O (2005) Differential effects of 20-hydroxyeicosatetraenoic acid on intrarenal blood flow in the rat. J Pharmacol Exp Ther 313:1289-95

Showing the most recent 10 out of 36 publications